Business ❯ Healthcare ❯ Pharmaceuticals

Clinical Trials

Drug Development Regulatory Compliance Product Compliance RAP-219 Program Product Development Obesity Treatments Breast Cancer Immunotherapy MariTide Major Depressive Disorder Phase 1 Trial Market Competition COPD Treatment Type 2 Diabetes ADEPT-2 Study Investor Relations Drug Efficacy VX-993 Phase 3 Trials Cancer Treatments Pemvidutide AI in Healthcare Jasper Therapeutics DESTINY-Breast05 Hyalofast Essential Tremor Regulatory Approvals AstraZeneca Drug Candidates BMS and J&J Blood Thinner Phase 3 Results Kidney Disease Amgen

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

Trial monitors advised adding patients based on an independent review.

aTyr Investors Face Dec. 8 Deadline in Securities Suits Over Efzofitimod Trial Failure

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

FDA Setback Puts uniQure’s Huntington’s Gene Therapy Filing in Doubt

Viking Therapeutics Jumps After Wider Q3 Loss as R&D Ramp Signals Obesity-Drug Progress

Praxis Drug Succeeds in Two Phase 3 Essential Tremor Trials, FDA Filing Planned

Law Firms Urge Jasper Therapeutics Investors to Seek Lead‑Plaintiff Role Before Nov. 18 Deadline

Pfizer Lifts 2025 EPS Outlook, Targets $7.7 Billion in Savings as Dividend Draws Interest